Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Gas Research
Published in: Medical Gas Research 1/2013

Open Access 01-12-2013 | Review

XENON in medical area: emphasis on neuroprotection in hypoxia and anesthesia

Authors: Ecem Esencan, Simge Yuksel, Yusuf Berk Tosun, Alexander Robinot, Ihsan Solaroglu, John H Zhang

Published in: Medical Gas Research | Issue 1/2013

Login to get access

Abstract

Xenon is a medical gas capable of establishing neuroprotection, inducing anesthesia as well as serving in modern laser technology and nuclear medicine as a contrast agent. In spite of its high cost, its lack of side effects, safe cardiovascular and organoprotective profile and effective neuroprotective role after hypoxic-ischemic injury (HI) favor its applications in clinics. Xenon performs its anesthetic and neuroprotective functions through binding to glycine site of glutamatergic N-methyl-D-aspartate (NMDA) receptor competitively and blocking it. This blockage inhibits the overstimulation of NMDA receptors, thus preventing their following downstream calcium accumulating cascades. Xenon is also used in combination therapies together with hypothermia or sevoflurane. The neuroprotective effects of xenon and hypothermia cooperate synergistically whether they are applied synchronously or asynchronously. Distinguishing properties of Xenon promise for innovations in medical gas field once further studies are fulfilled and Xenon’s high cost is overcome.
Appendix
Available only for authorised users
Literature
1.
Liu W, Khatibi N, Sridharan A, Zhang JH: Application of medical gases in the field of neurobiology. Med Gas Res. 2011, 1: 13-10.1186/2045-9912-1-13.PubMedCentralPubMed
2.
Christl SU, Murgatroyd PR, Gibson GR, Cummings JH: Production, metabolism, and excretion of hydrogen in the large intestine. Gastroenterology. 1992, 102: 1269-1277.PubMed
3.
Hammer HF: Colonic hydrogen absorption: quantification of its effect on hydrogen accumulation caused by bacterial fermentation of carbohydrates. Gut. 1993, 34: 818-822. 10.1136/gut.34.6.818.PubMedCentralPubMed
4.
Ohsawa I, Ishikawa M, Takahashi K, Watanabe M, Nishimaki K, Yamagata K, Katsura K-I, Katayama Y, Asoh S, Ohta S: Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med. 2007, 13: 688-694. 10.1038/nm1577.PubMed
5.
Cai J, Kang Z, Liu WW, Luo X, Qiang S, Zhang JH, Ohta S, Sun X, Xu W, Tao H, Li R: Hydrogen therapy reduces apoptosis in neonatal hypoxia-ischemia rat model. Neurosci Lett. 2008, 441: 167-172. 10.1016/j.neulet.2008.05.077.PubMed
6.
Cai J, Kang Z, Liu K, Liu W, Li R, Zhang JH, Luo X, Sun X: Neuroprotective effects of hydrogen saline in neonatal hypoxia-ischemia rat model. Brain Res. 2009, 1256: 129-137.PubMed
7.
Domoki F, Oláh O, Zimmermann A, Németh I, Tóth-Szuki V, Hugyecz M, Temesvári P, Bari F: Hydrogen is neuroprotective and preserves cerebrovascular reactivity in asphyxiated newborn pigs. Pediatr Res. 2010, 68: 387-392.PubMed
8.
Heinen A, Huhn R, Smeele KMA, Zuurbier CJ, Schlack W, Preckel B, Weber NC, Hollmann MW: Helium-induced preconditioning in young and old rat heart: impact of mitochondrial Ca(2+) -sensitive potassium channel activation. Anesthesiology. 2008, 109: 830-836. 10.1097/ALN.0b013e3181895aa0.PubMed
9.
Pagel PS, Krolikowski JG, Pratt PF, Shim YH, Amour J, Warltier DC, Weihrauch D: Reactive oxygen species and mitochondrial adenosine triphosphate-regulated potassium channels mediate helium-induced preconditioning against myocardial infarction in vivo. J Cardiothorac Vasc Anesth. 2008, 22: 554-559. 10.1053/j.jvca.2008.04.005.PubMedCentralPubMed
10.
Pagel PS, Krolikowski JG, Pratt PF, Shim YH, Amour J, Warltier DC, Weihrauch D: The mechanism of helium-induced preconditioning: a direct role for nitric oxide in rabbits. Anesth Analg. 2008, 107: 762-768. 10.1213/ane.0b013e3181815995.PubMedCentralPubMed
11.
Buras JA, Stahl GL, Svoboda KK, Reenstra WR: Hyperbaric oxygen downregulates ICAM-1 expression induced by hypoxia and hypoglycemia: the role of NOS. Am J Physiol Cell Physiol. 2000, 278: C292-C302.PubMed
12.
Jawad N, Rizvi M, Gu J, Adeyi O, Tao G, Maze M, Ma D: Neuroprotection (and lack of neuroprotection) afforded by a series of noble gases in an in vitro model of neuronal injury. Neurosci Lett. 2009, 460: 232-236. 10.1016/j.neulet.2009.05.069.PubMed
13.
Nakao A, Sugimoto R, Billiar TR, McCurry KR: Therapeutic antioxidant medical gas. J Clin Biochem Nutr. 2009, 44: 1-13. 10.3164/jcbn.08-193R.PubMedCentralPubMed
14.
Kelen D, Robertson NJ: Experimental treatments for hypoxic ischaemic encephalopathy. Early Hum Dev. 2010, 86: 369-377. 10.1016/j.earlhumdev.2010.05.011.PubMed
15.
Joyce JA: Xenon: anesthesia for the 21st century. AANA J. 2000, 68: 259-264.PubMed
16.
17.
Dworschak M: Pharmacologic neuroprotection–is xenon the light at the end of the tunnel?. Crit Care Med. 2008, 36: 2477-2479. 10.1097/CCM.0b013e31818113d2.PubMed
18.
David HN, Haelewyn B, Rouillon C, Lecoq M, Chazalviel L, Apiou G, Risso J-J, Lemaire M, Abraini JH: Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia. FASEB J. 2008, 22: 1275-1286.PubMed
19.
Sanders RD, Maze M: Xenon: from stranger to guardian. Curr Opin Anaesthesiol. 2005, 18: 405-411. 10.1097/01.aco.0000174957.97759.f6.PubMed
20.
Rizvi M, Jawad N, Li Y, Vizcaychipi MP, Maze M, Ma D: Effect of noble gases on oxygen and glucose deprived injury in human tubular kidney cells. Exp Biol Med (Maywood). 2010, 235: 886-891. 10.1258/ebm.2010.009366.
21.
Lane GA, Nahrwold ML, Tait AR, Taylor-Busch M, Cohen PJ, Beaudoin AR: Anesthetics as teratogens: nitrous oxide is fetotoxic, xenon is not. Science. 1980, 210: 899-901. 10.1126/science.7434002.PubMed
22.
Preckel B, Weber NC, Sanders RD, Maze M, Schlack W: Molecular mechanisms transducing the anesthetic, analgesic, and organ-protective actions of xenon. Anesthesiology. 2006, 105: 187-197. 10.1097/00000542-200607000-00029.PubMed
23.
de Vreede-Swagemakers JJ, Gorgels AP, Dubois-Arbouw WI, van Ree JW, Daemen MJ, Houben LG, Wellens HJ: Out-of-hospital cardiac arrest in the 1990’s: a population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol. 1997, 30: 1500-1505. 10.1016/S0735-1097(97)00355-0.PubMed
24.
Zheng ZJ, Croft JB, Giles WH, Mensah GA: Sudden cardiac death in the United States, 1989 to 1998. Circulation. 2001, 104: 2158-2163. 10.1161/hc4301.098254.PubMed
25.
Stiell IG, Wells GA, Field B, Spaite DW, Nesbitt LP, De Maio VJ, Nichol G, Cousineau D, Blackburn J, Munkley D, Luinstra-Toohey L, Campeau T, Dagnone E, Lyver M: Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J Med. 2004, 351: 647-656. 10.1056/NEJMoa040325.PubMed
26.
Hallstrom AP, Ornato JP, Weisfeldt M, Travers A, Christenson J, McBurnie MA, Zalenski R, Becker LB, Schron EB, Proschan M: Public-access defibrillation and survival after out-of-hospital cardiac arrest. N Engl J Med. 2004, 351: 637-646.PubMed
27.
Engdahl J, Bång A, Lindqvist J, Herlitz J: Time trends in long-term mortality after out-of-hospital cardiac arrest, 1980 to 1998, and predictors for death. Am Heart J. 2003, 145: 826-833. 10.1016/S0002-8703(03)00074-7.PubMed
28.
Nichol G, Stiell IG, Laupacis A, Pham B, De Maio VJ, Wells GA: A cumulative meta-analysis of the effectiveness of defibrillator-capable emergency medical services for victims of out-of-hospital cardiac arrest. Ann Emerg Med. 1999, 34: 517-525. 10.1016/S0196-0644(99)80054-7.PubMed
29.
Hossmann KA: Reperfusion of the brain after global ischemia: hemodynamic disturbances. Shock. 1997, 8: 95-101. 10.1097/00024382-199708000-00004. discussion 102–103PubMed
30.
Radovsky A, Safar P, Sterz F, Leonov Y, Reich H, Kuboyama K: Regional prevalence and distribution of ischemic neurons in dog brains 96 hours after cardiac arrest of 0 to 20 minutes. Stroke. 1995, 26: 2127-2133. 10.1161/01.STR.26.11.2127. discussion 2133–2134PubMed
31.
Ouyang YB, Tan Y, Comb M, Liu CL, Martone ME, Siesjö BK, Hu BR: Survival- and death-promoting events after transient cerebral ischemia: phosphorylation of Akt, release of cytochrome C and activation of caspase-like proteases. J Cereb Blood Flow Metab. 1999, 19: 1126-1135.PubMed
32.
Rockwood K, Brown M, Merry H, Sketris I, Fisk J: Societal costs of vascular cognitive impairment in older adults. Stroke. 2002, 33: 1605-1609. 10.1161/01.STR.0000017878.85274.44.PubMed
33.
Hopkins RO, Jackson JC: Long-term neurocognitive function after critical illness. Chest. 2006, 130: 869-878. 10.1378/chest.130.3.869.PubMed
34.
Zola-Morgan S, Squire LR, Rempel NL, Clower RP, Amaral DG: Enduring memory impairment in monkeys after ischemic damage to the hippocampus. J Neurosci. 1992, 12: 2582-2596.PubMed
35.
Rempel-Clower NL, Zola SM, Squire LR, Amaral DG: Three cases of enduring memory impairment after bilateral damage limited to the hippocampal formation. J Neurosci. 1996, 16: 5233-5255.PubMed
36.
Fries M, Nolte KW, Coburn M, Rex S, Timper A, Kottmann K, Siepmann K, Häusler M, Weis J, Rossaint R: Xenon reduces neurohistopathological damage and improves the early neurological deficit after cardiac arrest in pigs. Crit Care Med. 2008, 36: 2420-2426. 10.1097/CCM.0b013e3181802874.PubMed
37.
Chakkarapani E, Thoresen M, Hobbs CE, Aquilina K, Liu X, Dingley J: A closed-circuit neonatal xenon delivery system: a technical and practical neuroprotection feasibility study in newborn pigs. Anesth Analg. 2009, 109: 451-460. 10.1213/ane.0b013e3181aa9550.PubMed
38.
Parsons MW, Li T, Barber PA, Yang Q, Darby DG, Desmond PM, Gerraty RP, Tress BM, Davis SM: Combined (1)H MR spectroscopy and diffusion-weighted MRI improves the prediction of stroke outcome. Neurology. 2000, 55: 498-505. 10.1212/WNL.55.4.498.PubMed
39.
Dinse A, Föhr KJ, Georgieff M, Beyer C, Bulling A, Weigt HU: Xenon reduces glutamate-, AMPA-, and kainate-induced membrane currents in cortical neurones. Br J Anaesth. 2005, 94: 479-485. 10.1093/bja/aei080.PubMed
40.
Natale G, Cattano D, Abramo A, Forfori F, Fulceri F, Fornai F, Paparelli A, Giunta F: Morphological evidence that xenon neuroprotects against N-methyl-DL-aspartic acid-induced damage in the rat arcuate nucleus: a time-dependent study. Ann N Y Acad Sci. 2006, 1074: 650-658. 10.1196/annals.1369.063.PubMed
41.
Franks NP, Dickinson R, de Sousa SLM, Hall AC, Lieb WR: How does xenon produce anaesthesia?. Nature. 1998, 396: 324-324. 10.1038/24525.PubMed
42.
Hardingham GE, Bading H: The Yin and Yang of NMDA receptor signalling. Trends Neurosci. 2003, 26: 81-89. 10.1016/S0166-2236(02)00040-1.PubMed
43.
Dingley J, Tooley J, Porter H, Thoresen M: Xenon provides short-term neuroprotection in neonatal rats when administered after hypoxia-ischemia. Stroke. 2006, 37: 501-506. 10.1161/01.STR.0000198867.31134.ac.PubMed
44.
Ma D, Hossain M, Pettet GKJ, Luo Y, Lim T, Akimov S, Sanders RD, Franks NP, Maze M: Xenon preconditioning reduces brain damage from neonatal asphyxia in rats. J Cereb Blood Flow Metab. 2006, 26: 199-208. 10.1038/sj.jcbfm.9600184.PubMed
45.
Homi HM, Yokoo N, Ma D, Warner DS, Franks NP, Maze M, Grocott HP: The neuroprotective effect of xenon administration during transient middle cerebral artery occlusion in mice. Anesthesiology. 2003, 99: 876-881. 10.1097/00000542-200310000-00020.PubMed
46.
Luo Y, Ma D, Ieong E, Sanders RD, Yu B, Hossain M, Maze M: Xenon and sevoflurane protect against brain injury in a neonatal asphyxia model. Anesthesiology. 2008, 109: 782-789. 10.1097/ALN.0b013e3181895f88.PubMed
47.
Coburn M, Kunitz O, Baumert J-H, Hecker K, Haaf S, Zühlsdorff A, Beeker T, Rossaint R: Randomized controlled trial of the haemodynamic and recovery effects of xenon or propofol anaesthesia. Br J Anaesth. 2005, 94: 198-202. 10.1093/bja/aei023.PubMed
48.
Preckel B, Schlack W, Heibel T, Rütten H: Xenon produces minimal haemodynamic effects in rabbits with chronically compromised left ventricular function. Br J Anaesth. 2002, 88: 264-269. 10.1093/bja/88.2.264.PubMed
49.
Goto T, Saito H, Shinkai M, Nakata Y, Ichinose F, Morita S: Xenon provides faster emergence from anesthesia than does nitrous oxide-sevoflurane or nitrous oxide-isoflurane. Anesthesiology. 1997, 86: 1273-1278. 10.1097/00000542-199706000-00007.PubMed
50.
Spieth PM, Parotto M: Xenon and the developing brain. Minerva Anestesiol. 2011, 77: 565-566.PubMed
51.
Derwall M, Coburn M, Rex S, Hein M, Rossaint R, Fries M: Xenon: recent developments and future perspectives. Minerva Anestesiol. 2009, 75: 37-45.PubMed
52.
Smith WS: Pathophysiology of focal cerebral ischemia: a therapeutic perspective. J Vasc Interv Radiol. 2004, 15: S3-S12. 10.1097/01.RVI.0000108687.75691.0C.PubMed
53.
Horiguchi T, Snipes JA, Kis B, Shimizu K, Busija DW: Cyclooxygenase-2 mediates the development of cortical spreading depression-induced tolerance to transient focal cerebral ischemia in rats. Neuroscience. 2006, 140: 723-730. 10.1016/j.neuroscience.2006.02.025.PubMed
54.
Wilhelm S, Ma D, Maze M, Franks NP: Effects of xenon on in vitro and in vivo models of neuronal injury. Anesthesiology. 2002, 96: 1485-1491. 10.1097/00000542-200206000-00031.PubMed
55.
Bantel C, Maze M, Trapp S: Neuronal preconditioning by inhalational anesthetics. Anesthesiology. 2009, 110: 986-995. 10.1097/ALN.0b013e31819dadc7.PubMedCentralPubMed
56.
Tooley JR, Satas S, Porter H, Silver IA, Thoresen M: Head cooling with mild systemic hypothermia in anesthetized piglets is neuroprotective. Ann Neurol. 2003, 53: 65-72. 10.1002/ana.10402.PubMed
57.
58.
Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, Polin RA, Robertson CM, Thoresen M, Whitelaw A, Gunn AJ: Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet. 2005, 365: 663-670.PubMed
59.
Thoresen M, Hobbs CE, Wood T, Chakkarapani E, Dingley J: Cooling combined with immediate or delayed xenon inhalation provides equivalent long-term neuroprotection after neonatal hypoxia-ischemia. J Cereb Blood Flow Metab. 2009, 29: 707-714. 10.1038/jcbfm.2008.163.PubMed
60.
Chakkarapani E, Dingley J, Liu X, Hoque N, Aquilina K, Porter H, Thoresen M: Xenon enhances hypothermic neuroprotection in asphyxiated newborn pigs. Ann Neurol. 2010, 68: 330-341. 10.1002/ana.22016.PubMed
61.
Hobbs C, Thoresen M, Tucker A, Aquilina K, Chakkarapani E, Dingley J: Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. Stroke. 2008, 39: 1307-1313. 10.1161/STROKEAHA.107.499822.PubMed
62.
Martin JL, Ma D, Hossain M, Xu J, Sanders RD, Franks NP, Maze M: Asynchronous administration of xenon and hypothermia significantly reduces brain infarction in the neonatal rat. Br J Anaesth. 2007, 98: 236-240. 10.1093/bja/ael340.PubMed
63.
Rajakumaraswamy N, Ma D, Hossain M, Sanders RD, Franks NP, Maze M: Neuroprotective interaction produced by xenon and dexmedetomidine on in vitro and in vivo neuronal injury models. Neurosci Lett. 2006, 409: 128-133. 10.1016/j.neulet.2006.09.020.PubMed
64.
Dickinson R, Peterson BK, Banks P, Simillis C, Martin JCS, Valenzuela CA, Maze M, Franks NP: Competitive inhibition at the glycine site of the N-methyl-d-aspartate receptor by the anesthetics xenon and isoflurane. Anesthesiology. 2007, 107: 756-767. 10.1097/01.anes.0000287061.77674.71.PubMed
65.
Armstrong SP, Banks PJ, McKitrick TJW, Geldart CH, Edge CJ, Babla R, Simillis C, Franks NP, Dickinson R: Identification of Two mutations (F758W and F758Y) in the N-methyl-D-aspartate receptor glycine-binding site that selectively prevent competitive inhibition by xenon without affecting glycine binding. Anesthesiology. 2012, 117: 38-47. 10.1097/ALN.0b013e31825ada2e.PubMed
66.
Li M, Inoue K, Si H, Xiong Z: Calcium-permeable ion channels involved in glutamate receptor-independent ischemic brain injury. Acta Pharmacol Sin. 2011, 32: 734-740. 10.1038/aps.2011.47.PubMedCentralPubMed
67.
Fatokun AA, Stone TW, Smith RA: Adenosine receptor ligands protect against a combination of apoptotic and necrotic cell death in cerebellar granule neurons. Exp Brain Res. 2008, 186: 151-160. 10.1007/s00221-007-1218-3.PubMed
68.
Hardingham GE: Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans. 2009, 37: 1147-1160. 10.1042/BST0371147.PubMedCentralPubMed
69.
Choi DW: Calcium-mediated neurotoxicity: relationship to specific channel types and role in ischemic damage. Trends Neurosci. 1988, 11: 465-469. 10.1016/0166-2236(88)90200-7.PubMed
70.
Siesjö BK: Historical overview. Calcium, ischemia, and death of brain cells. Ann N Y Acad Sci. 1988, 522: 638-661. 10.1111/j.1749-6632.1988.tb33410.x.PubMed
71.
Solaroglu I, Solaroglu A, Kaptanoglu E, Dede S, Haberal A, Beskonakli E, Kilinc K: Erythropoietin prevents ischemia-reperfusion from inducing oxidative damage in fetal rat brain. Childs Nerv Syst. 2003, 19: 19-22.PubMed
72.
Verkhratsky A, Rodríguez JJ, Parpura V: Calcium signalling in astroglia. Mol Cell Endocrinol. 2012, 353: 45-56. 10.1016/j.mce.2011.08.039.PubMed
73.
Banks P, Franks NP, Dickinson R: Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor mediates xenon neuroprotection against hypoxia-ischemia. Anesthesiology. 2010, 112: 614-622. 10.1097/ALN.0b013e3181cea398.PubMed
74.
Abraini JH, David HN, Lemaire M: Potentially neuroprotective and therapeutic properties of nitrous oxide and xenon. Ann N Y Acad Sci. 2005, 1053: 289-300. 10.1196/annals.1344.025.PubMed
75.
Weng Y, Sun S: Therapeutic hypothermia after cardiac arrest in adults: mechanism of neuroprotection, phases of hypothermia, and methods of cooling. Crit Care Clin. 2012, 28: 231-243. 10.1016/j.ccc.2011.10.012.PubMed
76.
Bovill JG: Inhalation anaesthesia: from diethyl ether to xenon. Handb Exp Pharmacol. 2008, 182: 121-142. 10.1007/978-3-540-74806-9_6.PubMed
77.
78.
Franks NP, Lieb WR: Molecular and cellular mechanisms of general anaesthesia. Nature. 1994, 367: 607-614. 10.1038/367607a0.PubMed
79.
Baumert J-H, Hein M, Hecker KE, Satlow S, Neef P, Rossaint R: Xenon or propofol anaesthesia for patients at cardiovascular risk in non-cardiac surgery. Br J Anaesth. 2008, 100: 605-611. 10.1093/bja/aen050.PubMed
80.
Tonner PH: Xenon: one small step for anaesthesia… ?. Curr Opin Anaesthesiol. 2006, 19: 382-384. 10.1097/01.aco.0000236136.85356.13.PubMed
81.
Kratzer S, Mattusch C, Kochs E, Eder M, Haseneder R, Rammes G: Xenon attenuates hippocampal long-term potentiation by diminishing synaptic and extrasynaptic N-methyl-D-aspartate receptor currents. Anesthesiology. 2012, 116: 673-682. 10.1097/ALN.0b013e3182475d66.PubMed
82.
Ma D, Wilhelm S, Maze M, Franks NP: Neuroprotective and neurotoxic properties of the “inert” gas, xenon. Br J Anaesth. 2002, 89: 739-746. 10.1093/bja/89.5.739.PubMed
83.
Goto T, Suwa K, Uezono S, Ichinose F, Uchiyama M, Morita S: The blood-gas partition coefficient of xenon may be lower than generally accepted. Br J Anaesth. 1998, 80: 255-256. 10.1093/bja/80.2.255.PubMed
84.
Rossaint R, Reyle-Hahn M, Schulte Am Esch J, Scholz J, Scherpereel P, Vallet B, Giunta F, Del Turco M, Erdmann W, Tenbrinck R, Hammerle AF, Nagele P: Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. Anesthesiology. 2003, 98: 6-13. 10.1097/00000542-200301000-00005.PubMed
85.
Lynch C, Baum J, Tenbrinck R: Xenon anesthesia. Anesthesiology. 2000, 92: 865-868. 10.1097/00000542-200003000-00031.PubMed
86.
Horn NA, Hecker KE, Bongers B, Baumert HJ, Reyle-Hahn SM, Rossaint R: Coagulation assessment in healthy pigs undergoing single xenon anaesthesia and combinations with isoflurane and sevoflurane. Acta Anaesthesiol Scand. 2001, 45: 634-638. 10.1034/j.1399-6576.2001.045005634.x.PubMed
87.
de Rossi LW, Horn NA, Baumert JH, Gutensohn K, Hutschenreuter G, Rossaint R: Xenon does not affect human platelet function in vitro. Anesth Analg. 2001, 93: 635-10.1097/00000539-200109000-00020.PubMed
88.
Bedi A, Murray JM, Dingley J, Stevenson MA, Fee JPH: Use of xenon as a sedative for patients receiving critical care. Crit Care Med. 2003, 31: 2470-2477. 10.1097/01.CCM.0000089934.66049.76.PubMed
89.
Reinelt H, Marx T, Kotzerke J, Topalidis P, Luederwald S, Armbruster S, Schirmer U, Schmidt M: Hepatic function during xenon anesthesia in pigs. Acta Anaesthesiol Scand. 2002, 46: 713-716. 10.1034/j.1399-6576.2002.460614.x.PubMed
90.
Baumert J-H: Xenon-based anesthesia: theory and practice. Open Access Surgery. 2009, 2: 5-13.
91.
Sprung J, Abdelmalak B, Gottlieb A, Mayhew C, Hammel J, Levy PJ, O’Hara P, Hertzer NR: Analysis of risk factors for myocardial infarction and cardiac mortality after major vascular surgery. Anesthesiology. 2000, 93: 129-140. 10.1097/00000542-200007000-00023.PubMed
92.
Schmidt M, Marx T, Glöggl E, Reinelt H, Schirmer U: Xenon attenuates cerebral damage after ischemia in pigs. Anesthesiology. 2005, 102: 929-936. 10.1097/00000542-200505000-00011.PubMed
93.
Heurteaux C, Guy N, Laigle C, Blondeau N, Duprat F, Mazzuca M, Lang-Lazdunski L, Widmann C, Zanzouri M, Romey G, Lazdunski M: TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO J. 2004, 23: 2684-2695. 10.1038/sj.emboj.7600234.PubMedCentralPubMed
94.
Sanders RD, Ma D, Maze M: Xenon: elemental anaesthesia in clinical practice. Br Med Bull. 2004, 71: 115-135. 10.1093/bmb/ldh034.PubMed
95.
Georgiev SK, Furue H, Baba H, Kohno T: Xenon inhibits excitatory but not inhibitory transmission in rat spinal cord dorsal horn neurons. Mol Pain. 2010, 6: 25-10.1186/1744-8069-6-25.PubMedCentralPubMed
96.
Plested AJ, Wildman SS, Lieb WR, Franks NP: Determinants of the Sensitivity of AMPA Receptors to Xenon. Anesthesiology. 2004, 100: 347-358. 10.1097/00000542-200402000-00025.PubMed
97.
Burke J: Twin tracks: the unexpected origins of the modern world. 2003, New York: Simon & Schuster
98.
Spencer JM, Hadi SM: The excimer lasers. J Drugs Dermatol. 2004, 3: 522-525.PubMed
99.
Gauthier L: Astigmatism correction with excimer laser. J Fr Ophtalmol. 2012, 35: 206-211. 10.1016/j.jfo.2011.12.001.PubMed
100.
101.
Elmnasser N, Guillou S, Leroi F, Orange N, Bakhrouf A, Federighi M: Pulsed-light system as a novel food decontamination technology: a review. Can J Microbiol. 2007, 53: 813-821. 10.1139/W07-042.PubMed
102.
Folwaczny M, Liesenhoff T, Lehn N, Horch HH: Bactericidal action of 308 nm excimer-laser radiation: an in vitro investigation. J Endod. 1998, 24: 781-785. 10.1016/S0099-2399(98)80001-0.PubMed
103.
Morita A, Weiss M, Maeda A: Recent developments in phototherapy: treatment methods and devices. Recent Pat Inflamm Allergy Drug Discov. 2008, 2: 105-108. 10.2174/187221308784543665.PubMed
104.
Mavilia L, Mori M, Rossi R, Campolmi P, Puglisi Guerra A, Lotti T: 308 nm monochromatic excimer light in dermatology: personal experience and review of the literature. G Ital Dermatol Venereol. 2008, 143: 329-337.PubMed
105.
Nisticò SP, Saraceno R, Capriotti E, Felice CD, Chimenti S: Efficacy of monochromatic excimer light (308 nm) in the treatment of atopic dermatitis in adults and children. Photomed Laser Surg. 2008, 26: 14-18. 10.1089/pho.2007.2116.PubMed
106.
Ko NU, Achrol AS, Martin AJ, Chopra M, Saloner DA, Higashida RT, Young WL: Magnetic resonance perfusion tracks 133Xe cerebral blood flow changes after carotid stenting. Stroke. 2005, 36: 676-678. 10.1161/01.STR.0000155743.60019.e5.PubMed
107.
Coles JP: Imaging after brain injury. Br J Anaesth. 2007, 99: 49-60. 10.1093/bja/aem141.PubMed
108.
Latchaw RE, Yonas H, Hunter GJ, Yuh WTC, Ueda T, Sorensen AG, Sunshine JL, Biller J, Wechsler L, Higashida R, Hademenos G: Guidelines and recommendations for perfusion imaging in cerebral ischemia a scientific statement for healthcare professionals by the writing group on perfusion imaging, from the council on cardiovascular radiology of the American heart association. Stroke. 2003, 34: 1084-10.1161/01.STR.0000064840.99271.9E.PubMed
109.
Wintermark M, Sesay M, Barbier E, Borbély K, Dillon WP, Eastwood JD, Glenn TC, Grandin CB, Pedraza S, Soustiel J-F, Nariai T, Zaharchuk G, Caillé J-M, Dousset V, Yonas H: Comparative overview of brain perfusion imaging techniques. Stroke. 2005, 36: e83-e99. 10.1161/01.STR.0000177884.72657.8b.PubMed
110.
Kubota M, Murakami T, Nagano H, Eguchi H, Marubashi S, Kobayashi S, Wada H, Tanemura M, Dono K, Nakamori S, Sakon M, Monden M, Mori M, Doki Y: Xenon-inhalation computed tomography for noninvasive quantitative measurement of tissue blood flow in pancreatic tumor. Dig Dis Sci. 2012, 57: 801-805. 10.1007/s10620-011-1915-4.PubMed
111.
Mountz JM, Liu HG, Deutsch G: Neuroimaging in cerebrovascular disorders: measurement of cerebral physiology after stroke and assessment of stroke recovery. Semin Nucl Med. 2003, 33: 56-76. 10.1053/snuc.2003.127293.PubMed
112.
Saha G, Macintyre W, Go R: Radiopharmaceuticals for brain imaging. Semin Nucl Med. 1994, 24: 324-349. 10.1016/S0001-2998(05)80022-4.PubMed
113.
Goto T: Is there a future for xenon anesthesia?. Can J Anaesth. 2002, 49: 335-338. 10.1007/BF03017319.PubMed
114.
Bedi A, McBride WT, Armstrong MA, Murray JM, Fee JPH: Xenon has no effect on cytokine balance and adhesion molecule expression within an isolated cardiopulmonary bypass system. Br J Anaesth. 2002, 89: 546-550. 10.1093/bja/aef232.PubMed
115.
Torri G: Inhalation anesthetics: a review. Minerva Anestesiol. 2010, 76: 215-228.PubMed
Metadata
Title
XENON in medical area: emphasis on neuroprotection in hypoxia and anesthesia
Authors
Ecem Esencan
Simge Yuksel
Yusuf Berk Tosun
Alexander Robinot
Ihsan Solaroglu
John H Zhang
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Medical Gas Research / Issue 1/2013
Electronic ISSN: 2045-9912
DOI
https://doi.org/10.1186/2045-9912-3-4

Other articles of this Issue 1/2013

Medical Gas Research 1/2013 Go to the issue

Research

Xenon consumption during general surgery: a retrospective observational study

Research

Transperitoneal administration of dissolved hydrogen for peritoneal dialysis patients: a novel approach to suppress oxidative stress in the peritoneal cavity

Study protocol

Does hyperbaric oxygen therapy have the potential to improve salivary gland function in irradiated head and neck cancer patients?

Research

A comparative study on the anti-inflammatory effects of single oral doses of naproxen and its hydrogen sulfide (H2S)-releasing derivative ATB-346 in rats with carrageenan-induced synovitis

Review

Hypercapnia: is it protective in lung injury?

Case report

Safety of intravenous administration of hydrogen-enriched fluid in patients with acute cerebral ischemia: initial clinical studies
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits